Last reviewed · How we verify
Investigator's Choice of Therapy — Competitive Intelligence Brief
phase 3
Small molecule
Live · refreshed every 30 min
Target snapshot
Investigator's Choice of Therapy (Investigator's Choice of Therapy) — Zai Lab (Shanghai) Co., Ltd.. Investigator's Choice of Therapy is a flexible treatment approach where the treating physician selects from approved or standard-of-care therapeutic options based on individual patient characteristics.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Investigator's Choice of Therapy TARGET | Investigator's Choice of Therapy | Zai Lab (Shanghai) Co., Ltd. | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Investigator's Choice of Therapy CI watch — RSS
- Investigator's Choice of Therapy CI watch — Atom
- Investigator's Choice of Therapy CI watch — JSON
- Investigator's Choice of Therapy alone — RSS
Cite this brief
Drug Landscape (2026). Investigator's Choice of Therapy — Competitive Intelligence Brief. https://druglandscape.com/ci/investigator-s-choice-of-therapy. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab